Several malignant tumours have recently achieved personalized cancer treatment in clinical practice, such as anti-HER2 antibody for HER2-positive breast cancer, anti-EGFR therapy for KRAS wild-type colon cancer, and BRAF inhibitor for BRAF mutant melanoma [2–5]. This evidence concerns the gene BRAF and colonic neoplasm.